Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Yefenof

Showing results (1-10 of 102) with videos related to

Pageof 11
Sort By:
Advances in Experimental Medicine and Biology|July 18, 2000
Complement receptor 3 (CR3): a public transducer of innate immunity signals in macrophagesE Yefenof
Immunology|September 1, 1980
In vitro generation of cytotoxic lymphocytes against radiation and radiation leukaemia virus-induced tumours. II. A radiation-induced thymoma generates cytyotoxic response in syngeneic but not in allogeneic lymphocytesE Yefenof
Advances in Immunology|July 10, 1999
Murine models of thymic lymphomas: premalignant scenarios amenable to prophylactic therapyE Yefenof
Haematology and Blood Transfusion|January 1, 1979
Epstein Barr virus (EBV) and complement (C3) interactions with human lymphoid cellsE Yefenof
Experimental Cell Research|April 1, 1976
Difference in antibody induced redistribution of membrane IgM in EBV geonome free and EBV positive human lymphoid cellsE Yefenof, G Klein
International Journal of Cancer|September 15, 1977
Membrane receptor stripping confirms the association between EBV receptors and complement receptors on the surface of human B lymphoma linesE Yefenof, G Klein
Experimental Cell Research|October 1, 1974
Antibody-induced redistribution of normal and tumor associated surface antigensE Yefenof, G Klein
International Journal of Cancer|September 15, 1982
High- and low-leukemogenic variants of the radiation leukemia virus (RadLV) differ in ability to induce tumor-specific immune suppressionE Yefenof, D Zilcha
Nature|February 21, 1985
Interferon amplifies complement activation by Burkitt's lymphoma cellsE Yefenof, I McConnell
Advances in Cancer Research|January 1, 1995
Radiation leukemia virus-induced leukemogenesis: a paradigm of preleukemia and its control by preventive therapyE Yefenof, M Kotler
Pageof 11

Showing results (1-10 of 102) with videos related to

Sort By:
Pageof 11
Advances in Experimental Medicine and Biology|July 18, 2000
Complement receptor 3 (CR3): a public transducer of innate immunity signals in macrophagesE Yefenof
Immunology|September 1, 1980
In vitro generation of cytotoxic lymphocytes against radiation and radiation leukaemia virus-induced tumours. II. A radiation-induced thymoma generates cytyotoxic response in syngeneic but not in allogeneic lymphocytesE Yefenof
Advances in Immunology|July 10, 1999
Murine models of thymic lymphomas: premalignant scenarios amenable to prophylactic therapyE Yefenof
Haematology and Blood Transfusion|January 1, 1979
Epstein Barr virus (EBV) and complement (C3) interactions with human lymphoid cellsE Yefenof
Experimental Cell Research|April 1, 1976
Difference in antibody induced redistribution of membrane IgM in EBV geonome free and EBV positive human lymphoid cellsE Yefenof, G Klein
International Journal of Cancer|September 15, 1977
Membrane receptor stripping confirms the association between EBV receptors and complement receptors on the surface of human B lymphoma linesE Yefenof, G Klein
Experimental Cell Research|October 1, 1974
Antibody-induced redistribution of normal and tumor associated surface antigensE Yefenof, G Klein
International Journal of Cancer|September 15, 1982
High- and low-leukemogenic variants of the radiation leukemia virus (RadLV) differ in ability to induce tumor-specific immune suppressionE Yefenof, D Zilcha
Nature|February 21, 1985
Interferon amplifies complement activation by Burkitt's lymphoma cellsE Yefenof, I McConnell
Advances in Cancer Research|January 1, 1995
Radiation leukemia virus-induced leukemogenesis: a paradigm of preleukemia and its control by preventive therapyE Yefenof, M Kotler
Pageof 11